Testing KPL-387 for recurrent pericarditis

Exclusion

• −Has a history of immunosuppression, including positive human immunodeficiency virus (HIV) test results.
• −Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies
• −Has had a pericarditis recurrence in the last 3 months prior to BaselineBaselineYour starting measurements, taken before treatment begins.Read more →
• −Has received an investigational drug during the 4 weeks before study drug administration or is planning to receive an investigational drug at any time during the study.
• −Has a history of active or untreated, latent tuberculosis (TB) prior to screeningScreeningThe checks done before joining, to see whether a study fits.Read more →.
• −Has a history of immunodeficiency.
• −Has chest x-ray at Screening or within 12 weeks before first study drug administration, with evidence of malignancy, abnormality consistent with prior or active TB infection or active infection.
• −Has a history of malignancy of any organ system within the past 5 years before Screening (other than a successfully treated non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma and/or localized carcinoma in situ of the cervix).
• −Has a known or suspected current active infection or a history of chronic or recurrent infectious disease (\> 3 episodes in prior 12 months), including but not limited to, genitourinary infection, chest infection, sinusitis, or skin/soft tissue infection.
• −Has had a serious infection, has been admitted to the hospital for an infection, or has been treated for a documented infection requiring antibiotics for a documented infection within 2 weeks prior to first study drug administration.
• −Has had an organ transplant (except corneal transplant performed more than 3 months prior to first study drug administration).
• −In the InvestigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more →'s opinion, has any other medical condition that could adversely affect the subject's participation or interfere with study evaluations.